<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03683667</url>
  </required_header>
  <id_info>
    <org_study_id>00008000</org_study_id>
    <secondary_id>OPP1163259</secondary_id>
    <nct_id>NCT03683667</nct_id>
  </id_info>
  <brief_title>Protein Plus: Improving Infant Growth Through Diet and Enteric Health</brief_title>
  <acronym>JiVitA-6</acronym>
  <official_title>Efficacy of Supplemental Protein, Delivered Alone or in Combination With Treatment for Enteric Pathogens, to Prevent Growth Faltering in Bangladeshi Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins Bloomberg School of Public Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>International Centre for Diarrhoeal Disease Research, Bangladesh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bill and Melinda Gates Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins Bloomberg School of Public Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This cluster-randomized controlled trial is designed to address linear growth faltering in
      6-12-mo-old Bangladesh infants through a proof-of-concept package of interventions to a)
      increase intake of high quality protein and b) control enteric pathogens.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Stunting a major public health problem in Bangladesh, where 36% of children under the age of
      five are too short for their age. While dietary data indicate that protein intakes of infants
      and young children are largely in line with requirements, the extent to which requirements
      derived for healthy infants and young children are relevant in the context of frequent
      infections remains an important research question.

      Recent investigations indicate widespread pathogen carriage among Bangladeshi infants, with
      virtually all having at least one detectable pathogen in nondiarrheal stools by six months of
      age. Campylobacter and pathogenic E. Coli predominate in this setting. Enteric pathogens can
      compete with the host for available nutrients or alter nutrient metabolism. Acting via
      environmental enteric dysfunction, they can alter both digestion—through loss of digestive
      enzymes—and absorption of nutrients. Microbial translocation may further alter specific amino
      acid requirements.

      Even in the absence of acute diarrheal disease, enteric pathogen carriage is strongly
      associated with linear growth faltering. Combining the effects of high pathogen burden and
      poor diet, as indicated by low energy and protein from complementary foods, observational
      evidence suggests that the potentially preventable length-for-age Z-score deficit may be as
      high as 0.98.

      The present trial will test the combination of a) protein supplementation in the form of a
      protein-rich blended food or an egg, both fed daily to infants 6-12 months of age, and b)
      azithromycin treatment for enteric pathogens. The primary outcome will be change in
      length-for-age Z-score from the 6 to 12 months. Biochemical, microbiological and clinical
      intermediates will be measured to inform our secondary aims.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 23, 2018</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <intervention_model_description>For this 2 x 4 factorial, cluster-randomized trial, 566 previously defined clusters will be assigned independently to 8 different combinations of interventions: 1) azithromycin and protein supplementation; 2) azithromycin and isocaloric supplementation; 3) azithromycin and egg; 4) azithromycin and control (nutrition education); 5) placebo and protein supplementation; 6) placebo and isocaloric supplementation; 7) placebo and egg; 8) placebo and control (nutrition education).</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Participants, care providers, investigators and outcomes assessors will be blinded to the azithromycin or placebo interventions. Neither participants nor outcomes assessors will be masked to the nutrition interventions. Investigators will be masked to the nutrition interventions.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Length-for-age Z-score (LAZ) at 12 months of age</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Nutrient biomarkers</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Serum essential, conditionally essential amino acids and choline (by metabolomic analysis); retinol and tocopherols (HPLC); vitamin B12 (microbiological assay); zinc (AAS); ferritin and thyroglobulin (ELISA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Growth hormone and stress axes biomarkers</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Serum insulin-like growth factor 1 (IGF-1), IGF binding protein 3, cortisol, by ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Enteropathogen burden</measure>
    <time_frame>6, 6.5, 9, 9.5, 12, 15, and 18 months</time_frame>
    <description>Campylobacter, enterotoxigenic Escherichia coli (ETEC), enteroaggregative Escherichia coli (EAEC), enteropathogenic Escherichia coli (EPEC), Shigella and Cryptosporidium, by quantitative polymerase chain reaction (qPCR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gut microbiota composition</measure>
    <time_frame>6, 6.5, 9, 9.5, 12, 15, and 18 months</time_frame>
    <description>Microbial diversity and abundance, by 16S ribosomal RNA sequencing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Environmental enteric dysfunction biomarkers</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Stool myeloperoxidase and intestinal fatty acid-binding protein concentrations and plasma Endogenous endotoxin-core antibody (EndoCAb), by ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory biomarkers</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Plasma alpha-1 acid glycoprotein, C-reactive protein and interleukin-6, by ELISA; stool inflammatory cytokines, by ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone biomarkers</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Plasma collagen type X and N-Terminal Pro-C-Type Natriuretic Peptide (NT-ProCNP), by ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morbidity incidence</measure>
    <time_frame>6-12 months</time_frame>
    <description>Incident diarrhea/dysentery or respiratory infection, based on weekly recalls</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body composition</measure>
    <time_frame>6, 9, 12, 15, and 18 months</time_frame>
    <description>Fat mass by bioelectrical impedence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibiotic resistance</measure>
    <time_frame>6, 9, 12, 15, and 18 months</time_frame>
    <description>Resistance of commensal E. coli (stool) or S. pneumoniae (nasopharyngeal swab) to panel of antibiotics, by culture</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">3180</enrollment>
  <condition>Stunting</condition>
  <condition>Malnutrition; Protein</condition>
  <condition>Enteric Pathogens</condition>
  <condition>Campylobacter Infections</condition>
  <arm_group>
    <arm_group_label>Placebo &amp; Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo / Nutrition education</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo &amp; Protein Supplement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo / Protein-rich blended food / Nutrition education</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo &amp; Isocaloric Supplement</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo / Isocaloric blended food / Nutrition education</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo &amp; Egg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo / Egg / Nutrition education</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Azithromycin &amp; Control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Azithromycin / Nutrition education</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Azithromycin &amp; Protein Supplement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Azithromycin / Protein-rich blended food / Nutrition education</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Azithromycin &amp; Isocaloric Supplement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Azithromycin Isocaloric blended food Nutrition education</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Azithromycin and Egg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Azithromycin Egg Nutrition education</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin Oral Product</intervention_name>
    <description>Azithromycin oral suspension (10 mg/kg; 3 days) administered by study personnel at 6 and 9 months of age</description>
    <arm_group_label>Azithromycin &amp; Control</arm_group_label>
    <arm_group_label>Azithromycin &amp; Isocaloric Supplement</arm_group_label>
    <arm_group_label>Azithromycin &amp; Protein Supplement</arm_group_label>
    <arm_group_label>Azithromycin and Egg</arm_group_label>
    <other_name>Azithrocin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Contain inert excipients only</description>
    <arm_group_label>Placebo &amp; Control</arm_group_label>
    <arm_group_label>Placebo &amp; Egg</arm_group_label>
    <arm_group_label>Placebo &amp; Isocaloric Supplement</arm_group_label>
    <arm_group_label>Placebo &amp; Protein Supplement</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Protein Supplement</intervention_name>
    <description>Blended food providing 125 kcal and 10 g protein as egg white powder prepared as porridge and fed daily to infants from 6-12 months of age</description>
    <arm_group_label>Azithromycin &amp; Protein Supplement</arm_group_label>
    <arm_group_label>Placebo &amp; Protein Supplement</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Isocaloric Supplement</intervention_name>
    <description>Blended food providing 125 kcal and 1 g protein as rice powder prepared as porridge and fed daily to infants from 6-12 months of age</description>
    <arm_group_label>Azithromycin &amp; Isocaloric Supplement</arm_group_label>
    <arm_group_label>Placebo &amp; Isocaloric Supplement</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Egg</intervention_name>
    <description>Egg provided daily to infants from 6-12 months of age</description>
    <arm_group_label>Azithromycin and Egg</arm_group_label>
    <arm_group_label>Placebo &amp; Egg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Nutrition Education</intervention_name>
    <description>Monthly messaging on infant and young child feeding</description>
    <arm_group_label>Azithromycin &amp; Control</arm_group_label>
    <arm_group_label>Azithromycin &amp; Isocaloric Supplement</arm_group_label>
    <arm_group_label>Azithromycin &amp; Protein Supplement</arm_group_label>
    <arm_group_label>Azithromycin and Egg</arm_group_label>
    <arm_group_label>Placebo &amp; Control</arm_group_label>
    <arm_group_label>Placebo &amp; Egg</arm_group_label>
    <arm_group_label>Placebo &amp; Isocaloric Supplement</arm_group_label>
    <arm_group_label>Placebo &amp; Protein Supplement</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Born to women enrolled in ongoing community trial (NCT02909179) over a one-year period

        Exclusion Criteria:

          -  Born to women not registered as part of the ongoing community trial (NCT02909179)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>6 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amanda C Palmer, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins Bloomberg School of Public Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Md Iqbal Hossain, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>International Centre for Diarrhoel Disease Research, Bangladesh</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amanda C Palmer, PhD</last_name>
    <phone>443-287-5050</phone>
    <email>acpalmer@jhu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alain B Labrique, PhD</last_name>
    <phone>443-287-4744</phone>
    <email>alabriqu@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>JiVitA Maternal and Child &amp; Nutrition Research Site</name>
      <address>
        <city>Gaibandha</city>
        <country>Bangladesh</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hasmot Ali, MPH</last_name>
      <phone>+8801713163461</phone>
      <email>hasmot.jivita@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Saijuddin Shaikh, PhD</last_name>
      <phone>+8801713202561</phone>
      <email>saiju.jivita@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Alain B Labrique, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Bangladesh</country>
  </location_countries>
  <reference>
    <citation>Arsenault JE, Brown KH. Dietary Protein Intake in Young Children in Selected Low-Income Countries Is Generally Adequate in Relation to Estimated Requirements for Healthy Children, Except When Complementary Food Intake Is Low. J Nutr. 2017 May;147(5):932-939. doi: 10.3945/jn.116.239657. Epub 2017 Feb 15.</citation>
    <PMID>28202639</PMID>
  </reference>
  <reference>
    <citation>Uauy R. Keynote: rethinking protein. Food Nutr Bull. 2013 Jun;34(2):228-31.</citation>
    <PMID>23964397</PMID>
  </reference>
  <reference>
    <citation>Lang D; MAL-ED Network Investigators. Opportunities to assess factors contributing to the development of the intestinal microbiota in infants living in developing countries. Microb Ecol Health Dis. 2015 May 29;26:28316. doi: 10.3402/mehd.v26.28316. eCollection 2015.</citation>
    <PMID>26031686</PMID>
  </reference>
  <reference>
    <citation>MAL-ED Network Investigators . Relationship between growth and illness, enteropathogens and dietary intakes in the first 2 years of life: findings from the MAL-ED birth cohort study. BMJ Glob Health. 2017 Dec 28;2(4):e000370. doi: 10.1136/bmjgh-2017-000370. eCollection 2017.</citation>
    <PMID>29333282</PMID>
  </reference>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>September 21, 2018</study_first_submitted>
  <study_first_submitted_qc>September 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2018</study_first_posted>
  <last_update_submitted>December 6, 2018</last_update_submitted>
  <last_update_submitted_qc>December 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>linear growth</keyword>
  <keyword>infant feeding</keyword>
  <keyword>environmental enteric dysfunction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Campylobacter Infections</mesh_term>
    <mesh_term>Malnutrition</mesh_term>
    <mesh_term>Kwashiorkor</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

